|
|
In Case You Missed It: 2023 Impact Statement
We are proud to present the 2023 Impact Statement, highlighting ICRF’s commitment to supporting the best and brightest scientists in Israel working to end the suffering caused by cancer.
|
|
|
|
Learn about the difference that ICRF makes and why supporting cancer research conducted in Israel is crucial to the fight against cancer. Hear from the scientists and survivors featured in the Impact Statement. |
|
|
|
According to the World Health Organization, cervical cancer is the fourth most common cancer in women globally. WHO launched the first annual Day of Action for Cervical Cancer Elimination in 2020 when there were an estimated 604,000 new cases of cervical cancer. There were 342,000 deaths reported worldwide in 2020 from those diagnosed with this cancer. More than 14,000 women in the U.S. are diagnosed with invasive cervical cancer each year but If detected early, it is one of the most successfully treatable cancers through regular screening tests and the HPV vaccine. |
|
|
|
Spotlight on ICRF Researchers |
|
|
|
Tel Aviv University
Project Grant
Human cells have two sets of 23 chromosomes, one from each parent. In normal cell division, one copy of each chromosome goes to each “daughter cell.” Errors can occur in this process, changing the number and structure of chromosomes in cancer cells, and helping some cancer cells multiply. Prof. Ben-David studies chromothripsis, the shattering and restitching of a chromosome which occurs in some 50% of tumors. Why it matters: Prof. Ben-David hopes to identify cellular vulnerabilities associated with this phenomenon and ultimately inspire new chromothripsis-based therapies.
|
|
Hebrew University of Jerusalem
Acceleration Grant
Enhancers control gene expression in DNA, the process in which the information included in a gene is turned into a functional product. They can produce RNA called eRNA, and a chemical change to eRNA, m6A, is essential to enhancer activity. In cancer, metabolic and genetic modifications can affect m6A levels in other types of RNA, but little is known about how this affects the m6A of eRNAs and disease development. Why it matters: Dr. Drier’s and Dr. Rabani’s investigation aims to determine which modifications contribute to cancer development. They plan to test potential treatments that can reverse these changes by targeting enhancers.
|
|
|
|
Ben-Gurion University of the Negev
Project Grant
Matrix Metalloproteinases (MMPs) are a large family of enzymes whose abnormal activities contribute to cancer progression. Despite extensive efforts, there are no clinically approved therapeutic agents specific to individual MMPs. Prof. Papo’s team is working to engineer novel inhibitors for these well-established chemical targets in cancer therapy. Why it matters: Based on the results of multiple studies, Prof. Papo's team will craft approaches to enhance specificity that make these inhibitors useful in the clinic.
|
|
Hebrew University of Jerusalem
The Harvey and Gloria Kaylie Foundation Research Professorship Grant
Immunotherapy has had a dramatic effect on cancer treatment, but most cancer patients do not respond to the currently available immunotherapies. The activity of immune cells is regulated by activating inhibitory proteins, which suppress immune cell activity. Immunotherapy of tumors is largely based on medication that prevents inhibition of the immune system. Why it matters: Prof. Mandelboim’s team is working to identify new inhibitory proteins and hopes to develop new medications for these inhibitory proteins.
|
|
|
|
|
|
Colposcopy is a medical procedure that allows for a close examination of the cervix, vagina, and vulva. It is typically performed when abnormalities are detected during routine cervical cancer screening, such as in a Pap smear or HPV test. The procedure is carried out using a colposcope, a specialized instrument with a light and magnifying lens. A relatively quick outpatient procedure, a colposcopy is a valuable tool for investigating abnormalities found in cervical cancer screening tests. The information gathered from a colposcopy can help determine the appropriate course of action, whether it involves close monitoring, further testing, or treatment to address precancerous or cancerous conditions. |
|
|
|
|
|
ICRF Toronto Welcomes Alison Himel as Board President
Alison steps into this role with great enthusiasm, a wealth of experience, and a vision that aligns seamlessly with ICRF Toronto's aspirations. Her leadership qualities, coupled with her fresh perspectives, promise an exciting chapter ahead.
|
|
|
|
ICRF Montreal Welcomes Brigitte Fortin as CEO
ICRF's Montreal Chapter has announced the appointment of Brigitte Fortin as CEO.
Brigitte brings with her an extensive background in the nonprofit sector, complemented by a profound commitment to community engagement. Her time at organizations such as Federation CJA, Azrieli Schools Talmud Torah and Herzliah, and Arthritis Society Canada has been marked by transformative leadership and innovative strategies. Her expertise in these diverse environments speaks volumes about her adaptability and impact-driven approach.
With her rich experience in crafting successful marketing and communications strategies and leading high-impact fundraising campaigns, Brigitte has consistently showcased her exceptional leadership and project management skills. Brigitte’s deep connection to, and comprehensive understanding of the Montreal Jewish community significantly enhances her suitability for this role. Her talent for nurturing strong relationships, coupled with her strategic and innovative thinking, will make her a wonderful addition to the ICRF Montreal team.
|
|
|
|
|
|
Run with Team ICRF in the
United Airlines NYC Half Marathon
Make an impact in the fight against cancer by running with Team ICRF in the 2024 United Airlines NYC Half Marathon on Sunday, March 17!
Team ICRF is now accepting applications for guaranteed entry, but space is limited. Runners that already have guaranteed entry into the race are welcome to join our team and fundraise for ICRF.
|
|
|
|
|
-
Breast cancer vaccine now in early clinical trials: What to know (ABC News) A new vaccine targeting triple-negative breast cancer has just gone through a successful first round of clinical trials. The vaccine is currently being designed to prevent a recurrence for people who have already been treated for triple-negative breast cancer.
|
|
|
|
Follow Us on Social Media |
|
|
|
|
|
Looking to stay updated on all things ICRF in between newsletters? Follow us on social media! You can find us on Facebook, LinkedIn, X (formerly known as Twitter) , and Instagram. We’d love to connect with you and keep you informed.
We share news updates, event announcements, ICRF researcher profiles, and more!
|
|
|
|
|
|
With a planned gift to the Israel Cancer Research Fund (ICRF), you can make a meaningful impact on countless cancer patients and their loved ones for years to come. To learn more about including ICRF in your estate planning, please contact Alan Herman at alan.herman@icrfonline.org or call 347-218-5946.
|
|
|
|
|
|
